ArticleBMC cancer2022
Lymphocyte to C-reactive protein ratio could better predict the prognosis of patients with stage IV cancer.
Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Utility of High-Sensitivity Modified Glasgow Prognostic Score in Cancer Prognosis: A Systemic Review and Meta-Analysis.International journal of molecular sciences · 2023Pooled it
- A retrospective multicenter study: postoperative prognostic value of the lymphocyte-C-reactive protein ratio combined with the Ki-67 index in gallbladder cancer.Updates in surgery · 2026Article
- The Value of the Albumin-Myosteatosis Gauge in Predicting the Postoperative Outcomes of Non-Metastatic Gastric Cancer.Cancers · 2026Article
- Association between prognostic nutritional index and mortality in patients with sepsis-associated delirium: a retrospective cohort study using the MIMIC-IV database.BMC nutrition · 2026Article
- Prognostic value of systemic inflammation-modified Patient-Generated Subjective Global Assessment in advanced cancers: A large-scale retrospective cohort study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Article
- Prognostic utility of the C-reactive protein-albumin-lymphocyte (CALLY) index in metastatic renal cell carcinoma.BMC cancer · 2025Article
- Association of lymphocyte-to-C-reactive protein ratio with all-cause and cause-specific mortality among US cancer survivors.European journal of medical research · 2025Article
- Improving postoperative outcomes in patients with pancreatic cancer: Inflammatory and nutritional biomarkers.World journal of clinical oncology · 2025Article
- Role of lymphocyte-to-C-reactive protein ratio in forecasting microvascular obstruction in ST-segment elevation myocardial infarction post-percutaneous coronary intervention.Frontiers in cardiovascular medicine · 2025Article
- The Association of Inflammatory Related Markers with the Prognosis in Elderly Patients with Colorectal Cancer.Cancer management and research · 2024Article
- The preoperative hemoglobin, albumin, lymphocyte, and platelet score (HALP) as a prognostic indicator in patients with non-small cell lung cancer.Frontiers in nutrition · 2024Article
- Platelet-to-Lymphocyte Ratio (PLR) as the Prognostic Factor for Recurrence/Residual Disease in HSIL Patients After LEEP.Journal of inflammation research · 2023Article
- Development and validation of a new prognostic immune-inflammatory-nutritional score for predicting outcomes after curative resection for intrahepatic cholangiocarcinoma: A multicenter study.Frontiers in immunology · 2023Article
- Prognostic significance of the novel nutrition-inflammation marker of lymphocyte-C-reactive protein ratio in patients with nasopharyngeal carcinoma receiving concurrent chemoradiotherapy.Frontiers in nutrition · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSystemic inflammation is currently regarded as a hallmark of cancer. This study aimed to accurately clarify the prognostic value of various inflammatory markers in patients with stage IV cancer.
methodsThis study assessed 2,424 patients with cancer diagnosed with cancer in tumor, node, metastasis (TNM) stage IV. After evaluating the predictive value of 13 inflammatory indicators for patient prognosis using the C index, the lymphocyte C-reactive protein ratio (LCR) was selected to elucidate the prognostic and predictive values in patients with stage IV cancer. Kaplan-Meier and Cox proportional hazards regression models were used to analyze long-term survival.
resultsA total of 1,457 men (60.1%) and 967 women (39.9%) diagnosed with TNM stage IV cancer were enrolled. A ratio of 2,814 was defined as the optimal cut-off value for the LCR. The LCR was the most accurate prognosis predictor for patients with stage IV cancer among the 13 inflammatory nutritional markers evaluated. The multivariate-adjusted restricted cubic spline plot suggested that LCR had an L-shaped dose-response association with all-cause mortality risk. Patients with lower LCR levels tended to present with worse prognoses. Kaplan-Meier curves and log-rank test results showed that the high LCR groups (LCR ≥ 2,814) exhibited a better prognosis, whereas patients with stage IV cancer of different sex and tumor types (for example, gastrointestinal tumor, non-gastrointestinal tumor, and lung cancer) had a worse survival time.
conclusionThe LCR score can be regarded as a stable and useful biomarker to predict prognosis in patients with TNM stage IV compared to other evaluated inflammation indicators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.